logo

For the Inventor, By the Inventor

Kanagawa, Japan

Oncotherapy Science, Incorporated


USPTO Granted Patents = 149

% Expired Patents = 42.3



Forward Citations = 356

Loading Chart...
Loading Chart...

84 inventors (with patents filed for the assignee):

goldMedal Takuya Tsunoda (73 out of 73 patents)

silverMedal Yusuke Nakamura (54 out of 116 patents)

bronzeMedal Yusuke Nakamura (34 out of 65 patents)

4.  Shuichi Nakatsuru (33 out of 33 patents)

5.  Sachiko Yoshimura (32 out of 32 patents)

6.  Tomohisa Watanabe (30 out of 30 patents)

7.  Ryuji Ohsawa (28 out of 28 patents)

8.  Ryuji Osawa (27 out of 27 patents)

9.  Toyomasa Katagiri (23 out of 23 patents)

10.  Yasuharu Nishimura (19 out of 22 patents)

11.  Yoichi Furukawa (17 out of 19 patents)

12.  Hideaki Tahara (14 out of 17 patents)

13.  Yataro Daigo (11 out of 11 patents)

14.  Sachiko Yamashita (9 out of 9 patents)

15.  Tetsuro Hikichi (9 out of 9 patents)


Core Competencies:
Peptide Vaccines
Monoclonal Antibodies
Tumor-Targeting Agents
Cancer Treatment
Immune Response
Breast Cancer
FZD10 Antibodies
DEPDC1 Polypeptides
MELK Inhibitors
Th1 Cells
SPARC Peptides
Synovial Sarcoma

149 patents:

1. 12595289 - THERAPEUTIC AGENT FOR BREAST CANCER COMPRISING BIG3-PHB2 INTERACTION-INHIBITING PEPTIDE DERIVED FROM PHB2 (2026-04-07),
2. 12195559 - CDCA1-derived peptide and vaccine containing same (2025-01-14),
3. 11673915 - DEPDC1-derived peptide and vaccine containing same (2023-06-13),
4. 11598780 - Engineering lymphocytes with specific alpha and beta chains on their t-cell receptor (2023-03-07),
5. 11547723 - KOC1-derived peptide and vaccine including same (2023-01-10),
6. 11266729 - UBE2T peptides and vaccines containing the same (2022-03-08),
7. 11242365 - FOXM1-derived peptide, and vaccine including same (2022-02-08),
8. 11091517 - Peptide derivative and pharmaceutical composition containing same (2021-08-17),
9. 11079386 - Monoclonal antibody against FZD10 and use thereof (2021-08-03),
10. 11066477 - Monoclonal antibody against MELK and utilization thereof (2021-07-20),
11. 10793599 - MPHOSPH1-derived peptide, and vaccine including same (2020-10-06),
12. 10711047 - CDCA1 epitope peptides and vaccines containing the same (2020-07-14),
13. 10676514 - CDCA1-derived peptide and vaccine containing same (2020-06-09),
14. 10676508 - DEPDC1-derived peptide and vaccine containing same (2020-06-09),
15. 10669310 - Peptide for cancer treatment and pharmaceutical composition containing same (2020-06-02),
Oncotherapy Science, Incorporated is a biotechnology company focused on researching and developing innovative cancer therapies. With a team of expert scientists and researchers, the company aims to discover novel treatment approaches that can improve patient outcomes in various types of cancer. Oncotherapy Science collaborates with leading academic institutions and industry partners to advance scientific knowledge and translate discoveries into effective therapies. Their dedication to precision medicine and personalized cancer treatment drives their mission to make a meaningful impact in the field of oncology.
This text is generated by artificial intelligence and may not be accurate.

logo

Company Badge

USPTO Data Jan 1 1976 - Sep 15 2026

Oncotherapy Science, Incorporated
149 Patents

#27 in Kanagawa

#859 in Japan

#5,464 in the World

Kanagawa, JP
Kanagawa, Japan

Oncotherapy Science, Incorporated

Forward Citations = 356

84 inventors:

goldMedal Takuya Tsunoda (73 out of 73 patents)

silverMedal Yusuke Nakamura (54 out of 116 patents)

bronzeMedal Yusuke Nakamura (34 out of 65 patents)

4.  Shuichi Nakatsuru (33 out of 33 patents)

5.  Sachiko Yoshimura (32 out of 32 patents)

Please report any incorrect information to [email protected]
Loading…